The July 2026 FDA Peptide Hearing: What the Committee Decided
Seven peptides. Two days of live, on-the-record votes. Here is what the committee decided, how the meeting worked, and what the result really means for BPC-157 and the rest.
On July 23 and 24, 2026 the FDA's Pharmacy Compounding Advisory Committee voted on seven peptides. It recommended six for the 503A compounding list, BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax, and voted against one, emideltide. This is a recommendation to the FDA, not final approval, and no final decision has come since.
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted on seven of the most talked-about peptides in the country. The votes did not make any of them an approved drug, and they did not happen with a quiet show of hands. Committee members cast their votes verbally, one peptide at a time, on a public livestream. For a corner of medicine that usually moves in silence, it was unusually loud.
When the two days were over, the committee had recommended six of the seven peptides for legal compounding and turned one down. The road into that result was anything but ordinary, and it is worth understanding, because the votes went against the advice of the FDA's own scientists. Here is what happened, how the meeting worked, and what the result does and does not mean.
What the committee was deciding
The committee was reviewing whether seven peptides should be added to the 503A bulk substances list, the list that determines what licensed compounding pharmacies are legally allowed to prepare for patients. It is worth being precise about what this was and was not. It was a recommendation to the FDA, not a final ruling. The FDA usually follows its advisory committees, but it acts later, through a formal rulemaking process that typically runs into 2027. All seven peptides had already come off the FDA's restricted Category 2 list back in April 2026, so a "no" vote did not re-ban anything. It simply meant no clear legal compounding pathway for that peptide for now.
A "yes" vote was not approval, and a "no" vote was not a ban. The meeting decided whether the committee would recommend a legal compounding pathway. It was one step, an important one, in a process that continues well past July.
What the committee decided
Across the two days the committee recommended six of the seven peptides for the 503A list: BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax. It voted against one, emideltide, also sold as DSIP, in a close 7 to 6 vote with one abstention. The recommendations are nonbinding. Before any of these peptides can be legally compounded under Section 503A, the FDA has to accept the advice and carry it through formal notice-and-comment rulemaking, a process that typically runs into 2027.
What makes the result striking is who reached it, and over what. The FDA's own scientific staff had recommended against compounding the peptides, unanimously against the four voted on the first day, pointing to an effective absence of human clinical evidence. The committee that overruled them had been rebuilt only weeks earlier: of the eight members newly appointed in June, six run clinics that offer peptides, according to ABC News. None of that changes the science on any single peptide, but it is context a reader deserves, because "recommended" reads very differently once you know the panel voted against its own agency's scientists.
For the full breakdown of every vote, day one and day two, see the complete meeting results.
Background: the road to the vote
The lead-up matters, because the sequence is what convinced so many people this was not a routine review.
On June 30, the FDA's scientific staff recommended against compounding all seven, pointing to thin human evidence. Yet the committee that voted on July 23 and 24 had been rebuilt with members who brought peptide and compounding backgrounds. That gap, between the staff's caution and the committee's makeup, is what decided how the result landed.
How the two days worked
The meeting ran across two days at the FDA's White Oak campus, open to the public in person and online. Each peptide was discussed, nominators presented in support, the public commented, and then the committee voted, out loud, on the livestream.
Jul 23
Jul 24
The order mattered. BPC-157 was the most established and most requested peptide in the group, and it was voted on first. Its recommendation colored how people read everything that followed over the two days.
What the votes actually showed
The result was not a clean sweep in either direction. The committee weighed each peptide on its own merits rather than moving as a bloc. The better-known compounds cleared, BPC-157 and TB-500 among them, and the group ended with six of seven recommended. Only emideltide fell short. For the peptides that advanced, it was the most concrete step toward legal, pharmacy-based compounding access they had had in years, though it did not make any of them an approved drug.
The committee only recommends. The FDA decides later, through notice-and-comment rulemaking that typically extends into 2027. Even a favorable vote is the start of the next phase, not the finish line.
Why this one mattered
Advisory meetings are usually procedural footnotes. This one was different for a simple reason: the signals were mixed and public. The administration had been openly supportive of expanding access. The committee had been rebuilt, most of its new members carrying financial ties to peptide businesses. And yet the FDA's own scientists, weeks earlier, had recommended against. Rarely do you get that kind of visible tension in a live, on-the-record vote. That BPC-157, the headliner, voted first only sharpened it. The two days carried real consequences for how millions of people may legally access these compounds.
We tracked each vote as it landed. You can follow the running status of every peptide in the review on our FDA Peptide Watch.
The bottom line
Seven peptides, two days, live votes, and a setup nobody in this space had quite seen before. Six were recommended and one was turned down, but a recommendation, either way, is a step in a longer process rather than the final word. What is clear is that the result shapes the legal landscape for compounded peptides heading into 2027. Watch the votes, not the noise, and remember that the safest path to any of these remains a licensed clinician and pharmacy, whatever the committee decided.
Read more and follow along
Track every vote as it lands and explore our full library of evidence-first guides at peptidenav.com. For live updates through the hearing:
Sources and further reading
- FDA. Pharmacy Compounding Advisory Committee. www.fda.gov
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A. www.fda.gov
- FDA. Certain Bulk Drug Substances That May Present Significant Safety Risks. www.fda.gov
- FDA. Compounding and the FDA: Questions and Answers. www.fda.gov
This article summarizes publicly reported information as of July 2026 and is educational, not medical, legal, or financial advice. It does not recommend any product, company, or investment. Regulatory status can change quickly. Always consult a licensed healthcare professional.